15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 1 of 15

 
 

Smith & Nephew (NYSE:SNN)

Consensus Rating
Hold
Rating Score
2.4
Ratings Breakdown
2 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
N/A

About Smith & Nephew

Smith & Nephew logoSmith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
11/28/2023BarclaysUpgradeUnderweight ➝ Equal Weight
11/3/2023JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
10/31/2023HSBCUpgradeHold ➝ Buy
10/13/2023Stifel NicolausInitiated CoverageHold
8/8/2023UBS GroupUpgradeSell ➝ Neutral
4/27/2023HSBCDowngradeBuy ➝ Hold
4/11/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight
3/29/2023BarclaysDowngradeOverweight ➝ Underweight
3/7/2023Sanford C. BernsteinInitiated CoverageOutperform
3/1/2023Liberum CapitalUpgradeHold ➝ Buy
 

Trump’s last act as President (Ad)

You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines.

For the full story, click here.